[144] GoodRx Holdings, Inc. SEC Filing

Rhea-AI Filing Summary

GoodRx Holdings, Inc. (GDRX) filed a Form 144 indicating the intent to sell 6,828 Class A shares through Merrill Lynch on or after 07/03/2025. The proposed sale represents approximately 0.0068% of the 100.3 million shares outstanding and has an estimated aggregate market value of $32,159.88. The shares were originally acquired in a private placement on 10/15/2015. Filers related to Spectrum VII funds sold a total of 10,677 Class A shares over the past three months for gross proceeds of $43,706.29. No other financial metrics, earnings data, or corporate developments are disclosed in this notice.

Insights

Equity Analyst

TL;DR: Very small insider sale; negligible dilution or signal—overall neutral impact.

The filing covers the planned sale of 6,828 Class A shares, a fraction of GoodRx’s float. At roughly $32 k in value, it is immaterial to market liquidity or corporate control. Insider‐related sales can sometimes flag sentiment shifts, but the miniscule size and routine Rule 144 disclosure suggest no meaningful read-through for broader investors. The prior 10,677-share sales by related Spectrum VII entities were similarly modest. In my view, the filing is non-impactful for valuation, credit, or governance considerations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Merrill Lynch, Pierce, Fenner & Smith Incorporated 555 California Street 18th Floor San Francisco CA 94104	6828	32159.88	100300165	07/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	10/15/2015	Private Placement	Issuer			6828	10/15/2015	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Spectrum VII Investment Managers' Fund, LP 140 NEW MONTGOMERY ST FL 20 San Francisco CA 94105	Class A	06/06/2025	6828	27950.41
Spectrum VII Co-Investment Fund, LP 140 NEW MONTGOMERY ST FL 20 San Francisco CA 94105	Class A	06/06/2025	3849	15755.88

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many GoodRx (GDRX) shares are being sold under this Form 144?

The notice covers 6,828 Class A shares to be sold.

What percentage of GoodRx’s outstanding shares does the sale represent?

Approximately 0.0068% of the 100,300,165 shares outstanding.

When is the anticipated sale date for the shares?

The filer listed an approximate sale date of 07/03/2025.

What is the estimated market value of the proposed sale?

The aggregate market value is $32,159.88 based on the data provided.

Were there any recent sales by the same filer?

Yes. Spectrum VII funds sold 10,677 Class A shares on 06/06/2025 for gross proceeds of $43,706.29.